# Disc Medicine, Inc.: financial statements, quarterly

IRON · Nasdaq · CIK 1816736 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/iron.md) · [Financials](/companies/iron/financials.md) · [Filings](/companies/iron/filings.md) · [Insiders](/companies/iron/insiders.md)

Standardized line items from XBRL company facts. Each value links to its filing; d marks a value derived from year-to-date figures. Other view: [annual](/companies/iron/financials.md?period=annual).

## Income statement

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Research and development | $m | [14.4](/filings/0000950170-24-124650.md) | [22.6 d](/filings/0001193125-26-073602.md) | [23.7](/filings/0000950170-25-065069.md) | [23.5](/filings/0001816736-25-000007.md) | [24.7](/filings/0001193125-25-268200.md) | [24.8 d](/filings/0001193125-26-073602.md) | [27.8](/filings/0001193125-26-205192.md) | [46.3](/filings/0001193125-26-325034.md) | [50.3](/filings/0001193125-25-268200.md) | [46.2 d](/filings/0001193125-26-073602.md) | [45.9](/filings/0001193125-26-205192.md) | [46.9](/filings/0001193125-26-325034.md) |
| Selling, general and administrative | $m | not reported | not reported | [7.8](/filings/0000950170-25-065069.md) | [7.4](/filings/0001816736-25-000007.md) | [8.2](/filings/0001193125-25-268200.md) | [9.8 d](/filings/0001193125-26-073602.md) | [12.2](/filings/0001193125-26-205192.md) | [15.1](/filings/0001193125-26-325034.md) | [17.4](/filings/0001193125-25-268200.md) | [20.7 d](/filings/0001193125-26-073602.md) | [23.6](/filings/0001193125-26-205192.md) | [18.1](/filings/0001193125-26-325034.md) |
| Operating income | $m | [(19.0)](/filings/0000950170-24-124650.md) | [(29.7) d](/filings/0001193125-26-073602.md) | [(31.5)](/filings/0000950170-25-065069.md) | [(30.9)](/filings/0001816736-25-000007.md) | [(32.9)](/filings/0001193125-25-268200.md) | [(34.6) d](/filings/0001193125-26-073602.md) | [(39.9)](/filings/0001193125-26-205192.md) | [(61.4)](/filings/0001193125-26-325034.md) | [(67.7)](/filings/0001193125-25-268200.md) | [(67.0) d](/filings/0001193125-26-073602.md) | [(69.5)](/filings/0001193125-26-205192.md) | [(65.1)](/filings/0001193125-26-325034.md) |
| Interest expense | $m | not reported | not reported | [0.0](/filings/0000950170-25-065069.md) | [0.0](/filings/0001816736-25-000007.md) | [0.0](/filings/0001193125-25-268200.md) | [0.6 d](/filings/0001193125-26-073602.md) | [0.9](/filings/0001193125-26-205192.md) | [0.9](/filings/0001193125-26-325034.md) | [0.9](/filings/0001193125-25-268200.md) | [0.9 d](/filings/0001193125-26-073602.md) | [0.8](/filings/0001193125-26-205192.md) | [0.9](/filings/0001193125-26-325034.md) |
| Income tax | $m | [0.0](/filings/0000950170-24-124650.md) | [0.0 d](/filings/0001193125-26-073602.md) | [0.0](/filings/0000950170-25-065069.md) | [0.1](/filings/0001816736-25-000007.md) | [0.1](/filings/0001193125-25-268200.md) | [0.2 d](/filings/0001193125-26-073602.md) | [0.1](/filings/0001193125-26-205192.md) | [0.1](/filings/0001193125-26-325034.md) | [0.1](/filings/0001193125-25-268200.md) | [0.1 d](/filings/0001193125-26-073602.md) | [0.1](/filings/0001193125-26-205192.md) | [0.1](/filings/0001193125-26-325034.md) |
| Net income | $m | [(14.1)](/filings/0000950170-24-124650.md) | [(23.6) d](/filings/0001193125-26-073602.md) | [(26.9)](/filings/0001193125-25-268200.md) | [(26.4)](/filings/0001193125-25-268200.md) | [(26.6)](/filings/0001193125-25-268200.md) | [(29.5) d](/filings/0001193125-26-073602.md) | [(34.1)](/filings/0001193125-26-325034.md) | [(55.2)](/filings/0001193125-26-325034.md) | [(62.3)](/filings/0001193125-25-268200.md) | [(60.5) d](/filings/0001193125-26-073602.md) | [(63.5)](/filings/0001193125-26-325034.md) | [(59.5)](/filings/0001193125-26-325034.md) |
| Diluted EPS | $ per share | [(0.58)](/filings/0000950170-24-124650.md) | not reported | [(1.09)](/filings/0000950170-25-065069.md) | [(1.03)](/filings/0001816736-25-000007.md) | [(0.89)](/filings/0001193125-25-268200.md) | not reported | [(1.02)](/filings/0001193125-26-205192.md) | [(1.58)](/filings/0001193125-26-325034.md) | [(1.77)](/filings/0001193125-25-268200.md) | not reported | [(1.65)](/filings/0001193125-26-205192.md) | [(1.54)](/filings/0001193125-26-325034.md) |
| Basic EPS | $ per share | [(0.58)](/filings/0000950170-24-124650.md) | not reported | [(1.09)](/filings/0000950170-25-065069.md) | [(1.03)](/filings/0001816736-25-000007.md) | [(0.89)](/filings/0001193125-25-268200.md) | not reported | [(1.02)](/filings/0001193125-26-205192.md) | [(1.58)](/filings/0001193125-26-325034.md) | [(1.77)](/filings/0001193125-25-268200.md) | not reported | [(1.65)](/filings/0001193125-26-205192.md) | [(1.54)](/filings/0001193125-26-325034.md) |

- Research and development: us-gaap:ResearchAndDevelopmentExpense
- Selling, general and administrative: us-gaap:SellingGeneralAndAdministrativeExpense
- Operating income: us-gaap:OperatingIncomeLoss
- Interest expense: us-gaap:InterestExpenseNonoperating
- Income tax: us-gaap:IncomeTaxExpenseBenefit
- Net income: us-gaap:NetIncomeLoss
- Diluted EPS: us-gaap:EarningsPerShareDiluted
- Basic EPS: us-gaap:EarningsPerShareBasic

## Balance sheet

| Line item | Unit | Q3 FY2023 (2023-09-30) | FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Cash and equivalents | $m | [371](/filings/0000950170-23-061572.md) | [360](/filings/0000950170-25-028390.md) | [343](/filings/0000950170-24-056304.md) | [281](/filings/0000950170-24-093357.md) | [193](/filings/0000950170-24-124650.md) | [192](/filings/0001193125-26-073602.md) | [123](/filings/0000950170-25-065069.md) | [127](/filings/0001816736-25-000007.md) | [141](/filings/0001193125-25-268200.md) | [91.1](/filings/0001193125-26-325034.md) | [88.9](/filings/0001193125-26-205192.md) | [98.7](/filings/0001193125-26-325034.md) |
| Current assets | $m | [374](/filings/0000950170-23-061572.md) | [366](/filings/0000950170-25-028390.md) | [352](/filings/0000950170-24-056304.md) | [508](/filings/0000950170-24-093357.md) | [493](/filings/0000950170-24-124650.md) | [494](/filings/0001193125-26-073602.md) | [706](/filings/0000950170-25-065069.md) | [662](/filings/0001816736-25-000007.md) | [627](/filings/0001193125-25-268200.md) | [804](/filings/0001193125-26-325034.md) | [747](/filings/0001193125-26-205192.md) | [733](/filings/0001193125-26-325034.md) |
| Total assets | $m | [376](/filings/0000950170-23-061572.md) | [368](/filings/0000950170-25-028390.md) | [354](/filings/0000950170-24-056304.md) | [510](/filings/0000950170-24-093357.md) | [495](/filings/0000950170-24-124650.md) | [497](/filings/0001193125-26-073602.md) | [709](/filings/0000950170-25-065069.md) | [665](/filings/0001816736-25-000007.md) | [630](/filings/0001193125-25-268200.md) | [807](/filings/0001193125-26-325034.md) | [750](/filings/0001193125-26-205192.md) | [735](/filings/0001193125-26-325034.md) |
| Current liabilities | $m | [14.4](/filings/0000950170-23-061572.md) | [21.4](/filings/0000950170-25-028390.md) | [14.9](/filings/0000950170-24-056304.md) | [20.3](/filings/0000950170-24-093357.md) | [25.5](/filings/0000950170-24-124650.md) | [23.3](/filings/0001193125-26-073602.md) | [18.7](/filings/0000950170-25-065069.md) | [20.6](/filings/0001816736-25-000007.md) | [26.7](/filings/0001193125-25-268200.md) | [36.6](/filings/0001193125-26-325034.md) | [31.1](/filings/0001193125-26-205192.md) | [30.4](/filings/0001193125-26-325034.md) |
| Total liabilities | $m | [17.5](/filings/0000950170-23-061572.md) | [22.9](/filings/0000950170-25-028390.md) | [16.1](/filings/0000950170-24-056304.md) | [21.4](/filings/0000950170-24-093357.md) | [27.2](/filings/0000950170-24-124650.md) | [53.2](/filings/0001193125-26-073602.md) | [48.9](/filings/0000950170-25-065069.md) | [50.9](/filings/0001816736-25-000007.md) | [57.1](/filings/0001193125-25-268200.md) | [67.1](/filings/0001193125-26-325034.md) | [61.8](/filings/0001193125-26-205192.md) | [90.9](/filings/0001193125-26-325034.md) |
| Long-term debt | $m | not reported | [0.0](/filings/0000950170-25-028390.md) | not reported | not reported | not reported | [28.3](/filings/0001193125-26-073602.md) | [28.5](/filings/0000950170-25-065069.md) | [28.7](/filings/0001816736-25-000007.md) | [28.9](/filings/0001193125-25-268200.md) | [29.2](/filings/0001193125-26-325034.md) | [29.4](/filings/0001193125-26-205192.md) | [59.3](/filings/0001193125-26-325034.md) |
| Current portion of debt | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Shareholders' equity | $m | [359](/filings/0000950170-24-124650.md) | [345](/filings/0001193125-26-073602.md) | [338](/filings/0001193125-25-268200.md) | [489](/filings/0001193125-25-268200.md) | [468](/filings/0001193125-25-268200.md) | [444](/filings/0001193125-26-325034.md) | [660](/filings/0001193125-26-325034.md) | [614](/filings/0001193125-26-325034.md) | [573](/filings/0001193125-25-268200.md) | [740](/filings/0001193125-26-325034.md) | [688](/filings/0001193125-26-325034.md) | [644](/filings/0001193125-26-325034.md) |

- Cash and equivalents: us-gaap:CashAndCashEquivalentsAtCarryingValue
- Current assets: us-gaap:AssetsCurrent
- Total assets: us-gaap:Assets
- Current liabilities: us-gaap:LiabilitiesCurrent
- Total liabilities: us-gaap:Liabilities
- Long-term debt: us-gaap:LongTermDebt
- Current portion of debt: not reported
- Shareholders' equity: us-gaap:StockholdersEquity

## Cash flow

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Operating cash flow | $m | [(7.5) d](/filings/0000950170-24-124650.md) | [(17.8) d](/filings/0001193125-26-073602.md) | [(33.6)](/filings/0000950170-25-065069.md) | [(15.4) d](/filings/0001816736-25-000007.md) | [(17.4) d](/filings/0001193125-25-268200.md) | [(27.6) d](/filings/0001193125-26-073602.md) | [(41.4)](/filings/0001193125-26-205192.md) | [(47.9) d](/filings/0001193125-26-325034.md) | [(47.8) d](/filings/0001193125-25-268200.md) | [(43.3) d](/filings/0001193125-26-073602.md) | [(62.2)](/filings/0001193125-26-205192.md) | [(44.2) d](/filings/0001193125-26-325034.md) |
| Capital expenditure | $m | [0.0 d](/filings/0000950170-24-124650.md) | [0.0 d](/filings/0001193125-26-073602.md) | [0.1](/filings/0000950170-25-065069.md) | [(0.0) d](/filings/0001816736-25-000007.md) | [(0.0) d](/filings/0001193125-25-268200.md) | [0.4 d](/filings/0001193125-26-073602.md) | [0.9](/filings/0001193125-26-205192.md) | [0.0 d](/filings/0001193125-26-325034.md) | [0.0 d](/filings/0001193125-25-268200.md) | [0.0 d](/filings/0001193125-26-073602.md) | [0.0](/filings/0001193125-26-205192.md) | [0.0 d](/filings/0001193125-26-325034.md) |

- Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities
- Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment

## Shares

| Line item | Unit | Q3 FY2022 (2022-09-30) | Q1 FY2023 (2023-03-31) | Q2 FY2023 (2023-06-30) | Q3 FY2023 (2023-09-30) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Diluted shares (weighted) | millions of shares | [1.0](/filings/0000950170-23-061572.md) | [19.0](/filings/0000950170-24-056304.md) | [21.5](/filings/0000950170-24-093357.md) | [24.3](/filings/0000950170-24-124650.md) | [24.8](/filings/0000950170-25-065069.md) | [25.6](/filings/0001816736-25-000007.md) | [29.9](/filings/0001193125-25-268200.md) | [33.3](/filings/0001193125-26-205192.md) | [35.0](/filings/0001193125-26-325034.md) | [35.2](/filings/0001193125-25-268200.md) | [38.5](/filings/0001193125-26-205192.md) | [38.7](/filings/0001193125-26-325034.md) |

- Diluted shares (weighted): us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding

Shares outstanding: 38,392,844 at 2026-07-23, from the cover of the [10-Q filed 2026-07-30](/filings/0001193125-26-325034.md) (dei:EntityCommonStockSharesOutstanding).

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:48 ET. No prices; not investment advice.